Olomorasib Market Summary

Key Factors Driving Olomorasib Growth

1. Strong activity in previously treated KRAS G12C-positive NSCLC, including after another KRAS G12C inhibitor: A major potential driver is olomorasib's ability to retain activity after prior KRAS G12C therapy. In the Phase 1/2 LOXO-RAS-20001 study, patients with KRAS G12C-inhibitor-pretreated NSCLC achieved an ORR of 41% and median PFS of 8.1 months in an updated analysis. A 2026 peer-reviewed first-in-human publication reported 42% ORR and 8.2-month median PFS among 38 patients previously treated with a KRAS G12C inhibitor. This could give olomorasib a differentiated role as a next-generation option following treatment with an approved KRAS G12C inhibitor.

2. Potentially strong first-line efficacy with pembrolizumab could substantially enlarge the opportunity: Lilly is developing olomorasib + pembrolizumab in first-line KRAS G12C-mutated advanced NSCLC. In the Phase 1/2 study, the combination produced a 57.1% ORR overall, 73.9% ORR in first-line patients, and 90% ORR in first-line patients with PD-L1 ≥50%. Median PFS was 11.8 months overall, while median duration of response was 17.2 months. These data support the ongoing Phase III SUNRAY-01 trial, which includes approximately 1,016 patients and evaluates first-line olomorasib + pembrolizumab with or without chemotherapy.

3. Meaningful CNS activity addresses an important unmet need in KRAS G12C NSCLC: Brain metastases are a significant challenge in advanced NSCLC, and olomorasib has demonstrated preliminary intracranial activity. In patients with active, untreated brain metastases from the LOXO-RAS-20001 study, intracranial ORR was 44.4% and intracranial disease-control rate was 83.3%; median time to intracranial response was only 2 months, while median intracranial DOR and PFS had not yet been reached at the data cutoff. This CNS activity could become an important differentiating factor if confirmed in larger randomized trials.

4. Expansion into early-stage/resected NSCLC could create a much larger treatment window: Lilly initiated the Phase III SUNRAY-02 study evaluating olomorasib with standard of care in resected or unresectable KRAS G12C-mutant NSCLC. The study is designed to assess disease-free survival and includes approximately 700 patients, with primary completion estimated in 2029. Success in this setting would move olomorasib beyond treatment of advanced disease and allow therapy to be used earlier in the patient's disease course, potentially increasing duration of treatment and the addressable population.

5. Pan-tumor activity creates additional lifecycle-expansion opportunities, particularly pancreatic cancer: The 2026 first-in-human publication showed activity across 14 different tumor histologies. In non-CRC solid tumors, olomorasib produced a 37.4% ORR, 89.5% disease-control rate and 6.9-month median PFS. Pancreatic cancer is particularly interesting because KRAS mutations occur in about 90% of pancreatic cancers, although the G12C subtype is much rarer at approximately 1–2%. Lilly received FDA Breakthrough Therapy designation in August 2026 for olomorasib monotherapy in previously treated advanced KRAS G12C-mutated pancreatic cancer, providing regulatory validation of this additional opportunity.

6. Regulatory acceleration and broad Phase III development increase the probability of commercialization: Olomorasib received FDA Breakthrough Therapy designation in September 2025 in combination with pembrolizumab for first-line KRAS G12C-mutated advanced/metastatic NSCLC with PD-L1 ≥50%. It subsequently received a second Breakthrough Therapy designation in August 2026 for previously treated KRAS G12C-mutated pancreatic cancer. Lilly is simultaneously advancing Phase III programs in first-line metastatic NSCLC and early-stage/resected NSCLC, increasing the likelihood of multiple potential indications rather than relying on a single approval.

Olomorasib Recent Developments

In August 2026, Amplia Therapeutics Limited announced that it entered into a Clinical Trial Collaboration and Supply Agreement ("CTCSA") with Eli Lilly & Company ("Lilly"), to evaluate the combination of Amplia's investigational FAK inhibitor, narmafotinib, with Lilly's investigational KRAS G12C inhibitor, olomorasib. The Phase Ib/IIb clinical trial will evaluate the safety and efficacy of this novel targeted therapy combination as a second line treatment in patients with advanced stage non-small cell lung cancer (NSCLC).

“Olomorasib Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Olomorasib for potential indication like Non-small cell lung cancer and Solid tumours in the 7MM. A detailed picture of Olomorasib’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Olomorasib for potential indications. The Olomorasib market report provides insights about Olomorasib’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Olomorasib performance, future market assessments inclusive of the Olomorasib market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Olomorasib sales forecasts, along with factors driving its market.

Olomorasib Drug Summary

Olomorasib (LY3537982) is an investigational, orally administered, potent and highly selective second-generation covalent inhibitor of the KRAS G12C mutant protein, developed by Eli Lilly for the treatment of KRAS G12C-mutated solid tumors, particularly non-small cell lung cancer (NSCLC). By selectively targeting the mutant KRAS G12C protein and inhibiting KRAS G12C-dependent signaling, olomorasib is designed to suppress oncogenic pathways that drive tumor-cell proliferation and survival. The molecule has pharmacokinetic properties intended to achieve high target occupancy and potency, supporting its evaluation both as monotherapy and in combination with other anticancer therapies. Olomorasib is currently being evaluated in Phase 3 studies, including SUNRAY-01 in combination with pembrolizumab with or without chemotherapy for first-line advanced KRAS G12C-mutated NSCLC and SUNRAY-02 in combination with immunotherapy for resected or unresectable KRAS G12C-mutated NSCLC. In August 2026, the U.S. FDA granted Breakthrough Therapy designation to olomorasib as monotherapy for previously treated advanced KRAS G12C-mutated pancreatic cancer, adding to its earlier Breakthrough Therapy designation for first-line KRAS G12C-mutated NSCLC with PD-L1 expression ≥50% in combination with pembrolizumab. As an investigational therapy, its safety and efficacy for these indications have not yet been established and it is not currently FDA-approved. The report provides Olomorasib’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Olomorasib Market Report

The report provides insights into:

• A comprehensive product overview including the Olomorasib MoA, description, dosage and administration, research and development activities in potential indication like Non-small cell lung cancer and Solid tumours.
• Elaborated details on Olomorasib regulatory milestones and other development activities have been provided in Olomorasib market report.
• The report also highlights Olomorasib‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Olomorasib market report also covers the patents information, generic entry and impact on cost cut.
• The Olomorasib market report contains current and forecasted Olomorasib sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Olomorasib market report also features the SWOT analysis with analyst views for Olomorasib in potential indications.

Methodology

The Olomorasib market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Olomorasib Analytical Perspective by DelveInsight

• In-depth Olomorasib Market Assessment

This Olomorasib sales market forecast report provides a detailed market assessment of Olomorasib for potential indication like Non-small cell lung cancer and Solid tumours in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Olomorasib sales data uptil 2034.

• Olomorasib Clinical Assessment

The Olomorasib market report provides the clinical trials information of Olomorasib for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Olomorasib Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Olomorasib Market Potential & Revenue Forecast

• Projected market size for the Olomorasib and its key indications
• Estimated Olomorasib sales potential (Olomorasib peak sales forecasts)
• Olomorasib Pricing strategies and reimbursement landscape

Olomorasib Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Olomorasib Market positioning compared to existing treatments
• Olomorasib Strengths & weaknesses relative to competitors

Olomorasib Regulatory & Commercial Milestones

• Olomorasib Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Olomorasib Clinical Differentiation

• Olomorasib Efficacy & safety advantages over existing drugs
• Olomorasib Unique selling points

Olomorasib Market Report Highlights

• In the coming years, the Olomorasib market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Olomorasib companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Olomorasib’s dominance.
• Other emerging products for Non-small cell lung cancer and Solid tumours are expected to give tough market competition to Olomorasib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Olomorasib in potential indications.
• Analyse Olomorasib cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Olomorasib sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Olomorasib in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Olomorasib? How strong is Olomorasib’s clinical and commercial performance?
• What is Olomorasib’s clinical trial status in each individual indications such as Non-small cell lung cancer and Solid tumours and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Olomorasib Manufacturers?
• What are the key designations that have been granted to Olomorasib for potential indications? How are they going to impact Olomorasib’s penetration in various geographies?
• What is the current and forecasted Olomorasib market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Olomorasib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Olomorasib for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Olomorasib? What is the duration of therapy and what are the geographical variations in cost per patient?